Showing 1991-2000 of 3564 results for "".
- Oxidative Stress Linked with Acne Severity: Analysishttps://practicaldermatology.com/news/circulating-biomarkers-of-oxidative-stress-in-acne-vulgaris/2462438/Biomarkers of oxidative stress correlated with the severity of acne vulgaris, according to a recent review published in the Archives of Dermatological Research. "The relationship between acne vulgaris and oxidative stress biomarkers lacks a clear consensus," the authors wrote. "
- Almirall Partners with Eloxx Pharmaceuticals to Target Rare Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-partners-with-eloxx-pharmaceuticals-to-target-rare-dermatological-diseases/2462435/Almirall and Eloxx Pharmaceuticals, Inc., announced today that they have partnered to exclusively license ZKN-013, in what they call a "potential game-changer" for the treatment of rare dermatological disorders. The agreement grants Almirall global rights to develop
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experienci
- Long-acting Reversible Contraception Linked with Acne Young Adults: Analysishttps://practicaldermatology.com/news/relationship-between-long-acting-reversible-contraception-and-acne-in-a-cohort-of-adolescents-and-young-adults/2462264/The use of progestin-only long-acting reversible contraception (LARC) may have an increased risk of developing acne or experiencing worsening of acne symptoms, a new analysis indicates. "Few studies have focused primarily on the effects of hormonal LARC on the developmen
- After Positive Phase 1 Results, Apogee to Test Twice-Yearly Dosing of Atopic Dermatitis Drug Candidatehttps://practicaldermatology.com/news/after-positive-phase-1-results-apogee-to-test-twice-yearly-dosing-of-atopic-dermatitis-drug-candidate/2462261/Apogee Therapeutics announced positive interim phase 1 data from its first-in-human study of APG777, one of its lead product candidates being developed as a frontline treatment for moderate-to-severe atopic dermatitis (AD) and other inflammatory diseases. Pharmacokinetic (PK) data showed a half-l
- Bimekizumab Not Linked with Depression, Suicidal Ideation in Moderate-to-Severe Psoriasishttps://practicaldermatology.com/news/mental-health-outcomes-in-patients-with-moderate-to-severe-psoriasis-treated-with-bimekizumab-analysis-of-phase-23-randomized-trials/2462260/A new analysis indicates that bimekizumab was not associated with a high risk of suicidal ideation/behavior (SIB) and depression. Psoriasis patients often face increased risks of SIB and depression, according to the researchers. Bimekizumab, an FDA-approved biologic inhibiting
- JAK-STAT Inhibitors Not Linked with Significant Increase in Cardiovascular Eventshttps://practicaldermatology.com/news/short-term-cardiovascular-complications-in-dermatology-patients-receiving-jak-stat-inhibitors/2462236/A new systematic review looking at the potential cardiovascular risks associated with Janus kinase–signal transducer and activator of transcription inhibitors (JAK-STATi) showed no safety signals in the short term. The findings bring a nuanced perspective on the safety profile of systemic
- Ceramide and Niacinamide-Containing Moisturizer Safe, Effective with Topical Acne Treatmenthttps://practicaldermatology.com/news/study-reveals-ceramide-and-niacinamide-containing-moisturizer-enhances-topical-acne-treatment/2462234/New research suggests that a moisturizer containing ceramides and niacinamide (CCM) significantly improved lesions from acne vulgaris when combined with anti-acne medication. "Dermatologists often suggests using moisturizers for a wide range of skin problems initiated by acne
- For Alopecia Areata, Discontinuation of Baricitinib Linked with Loss of Benefithttps://practicaldermatology.com/news/for-alopecia-areata-discontinuation-of-baricitinib-linked-with-loss-of-benefit/2462225/Results from a randomized substudy of the BRAVE-AA1 study suggested that patients with severe alopecia areata who withdrawal from treatment with baricitinib also lose the treatment benefit.
- Researchers Identify Factors Limiting New Treatment Decisions for HShttps://practicaldermatology.com/news/factors-affecting-treatment-selection-among-patients-with-hidradenitis-suppurativa/2462211/Researchers seeking to address the gap between evidence-based guidelines and clinical practice in the treatment of hidradenitis suppurativa (HS) have identified several factors influencing patient decision-making. The open-ended, two-center study, conducted through open-ended interviews